Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.50 |
| ▸ | AKT2 | P31751 | 3/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11095660 | 0.82 | MDM2 (0.53) | PDGFRAMAPK8CDK5CLK4AKT2 | |
| SCHEMBL6981427 | 0.77 | LMNA (0.47) | LMNAPDGFRAMAPK8CDK5CLK4 | |
| SCHEMBL21916800 | 0.76 | RAB9A (0.56) | LMNAPDGFRAMAPK8CDK5CLK4 | |
| SCHEMBL6129257 | 0.74 | PDGFRA (0.49) | LMNAPDGFRAMAPK8CDK5CLK4 | |
| SCHEMBL29761171 | 0.74 | LMNA (0.45) | LMNAPDGFRAMAPK8CDK5CLK4 | |
| SCHEMBL5145616 | 0.73 | LMNA (0.50) | LMNAPDGFRAMAPK8CDK5CLK4 | |
| SCHEMBL9701635 | 0.73 | LMNA (0.50) | LMNAPDGFRAMAPK8CDK5CLK4 | |
| SCHEMBL31567901 | 0.73 | LMNA (0.44) | LMNAPDGFRAMAPK8CDK5CLK4 | |
| SCHEMBL7298629 | 0.73 | LMNA (0.51) | LMNAPDGFRAMAPK8CDK5CLK4 | |
| SCHEMBL7772483 | 0.73 | LMNA (0.70) | LMNAPDGFRAMAPK8CDK5CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10973821-B2 | Pharmaceutical formulation | F2G LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| WO-2020070332-A1 | OXINDOLE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | ICHNOS SCIENCES S.A. (CH) | 2020-04-09 | — | — | WO | disclosed |
| US-20190328737-A1 | PHARMACEUTICAL FORMULATION | F2G LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| US-10201524-B2 | Antifungal agents | F2G LIMITED (GB) | 2019-02-12 | — | — | US | disclosed |
| US-20170340607-A1 | ANTIFUNGAL AGENTS | F2G LTD (GB) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190328737-A1 | PHARMACEUTICAL FORMULATION | DPM1, PIR, PLP2 | LMNA 3583/4885PDGFRA 1126/4885MAPK8 3869/4885 |
| US-20170340607-A1 | ANTIFUNGAL AGENTS | DPM1, AADAC, PIK3C3 | LMNA 4237/4885PDGFRA 2530/4885MAPK8 2318/4885 |
| US-10973821-B2 | Pharmaceutical formulation | DPM1, PIR, PFN1 | LMNA 3468/4885PDGFRA 1129/4885MAPK8 2794/4885 |
| US-10201524-B2 | Antifungal agents | DPM1, AADAC, PIK3C3 | LMNA 4256/4885PDGFRA 2681/4885MAPK8 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.